Radiation Device Allows for Targeted Breast Radiation to Control Cancer

 

July 12, 2010  |  

A new study of breast cancer patients at the Moores UCSD Cancer Center and the Arizona Oncology Services shows that after almost two years, the radiation given with the Strut-Adjusted Volume Implant (SAVI™) controls the rate of cancer and may reduce the complications seen with alternate types of brachytherapy. This study also demonstrates the accuracy and flexibility of the device to maximize the dose to the target tissue and minimize the exposure of healthy surrounding tissue and organs.

“This is the first paper that documents the patients’ status after almost two years,” said Catheryn Yashar, MD, associate professor of radiation oncology at the UC San Diego School of Medicine and chief of breast and gynecological radiation services at the Moores UCSD Cancer Center.   “After almost two years, the patients showed that the treatment was well-tolerated without experiencing significant side effects. To date, the control rate of cancer is also very promising.”

SAVI, which consists of comfortable, flexible catheters through which radiation is given, provides customized radiation therapy and minimizes exposure to healthy tissue after a woman who has undergone a lumpectomy to remove a cancerous tumor. Radiation specialists sometimes decide to give women internal radiation – a process called brachytherapy – with the goal of giving concentrated doses of radiation to areas of concern while avoiding healthy tissue.

These findings reported in the International Journal of Radiation Oncology, Biology and Physics showed the results of 102 patients treated at a median follow-up time of 21 months. The researchers found that the SAVI appears to safely allow an increase in eligibility for patients to receive Accelerated Partial Breast Irradiation (APBI) over balloon brachytherapy or three-dimensional conformal radiation.

“This treatment allows us to provide internal radiation to the area without damaging the healthy tissue around the site, and minimizes radiation to a duration of only five days,” explained Yashar.  “The traditional whole breast treatment usually takes approximately six weeks.”

Other authors of the clinical investigation include: Daniel Scanderbeg, Ph.D, Robert Kuske, MD, Anne Wallace, MD, Victor Zannis, MD, Sarah Blair, MD, Emily Grade, Virginia Swenson and Coral Quiet, MD.

The Moores UCSD Cancer Center is one of the nation’s 40 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer. For more information, visit http://cancer.ucsd.edu/    

# # #

Media Contact: Karen Shea, 619-543-6163, kshea@ucsd.edu




Media Contact

Share This Article


Related News

9/22/2017
More than 100 physicians from UC San Diego Health were named “Top Docs” in the annual San Diego Magazine “Physicians of Exceptional Excellence” annual survey. These physicians represent 45 diverse spe ...
9/21/2017
Chronic tissue inflammation resulting from obesity is an underlying cause of insulin resistance and type 2 diabetes. But the mechanism by which this occurs has remained cloaked, until now. In a paper, ...
9/21/2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego Sch ...
9/20/2017
Researchers at University of San Diego School of Medicine have developed a new tool called the San Diego Wisdom Scale (SD-WISE) to assess an individual’s level of wisdom, based upon a conceptualizatio ...



Follow Us